Rodolphe Thiebaut
Overview
Explore the profile of Rodolphe Thiebaut including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
241
Citations
6844
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, et al.
EClinicalMedicine
. 2024 Dec;
77:102845.
PMID: 39649135
Background: Current HIV prophylactic vaccines evaluate HIV Env as purified proteins. CD40.HIVRI.Env is an innovative antigen delivery targeting gp140 Env from HIV Clade C 96ZM651 to CD40-expressing antigen-presenting cells, thus...
2.
Valayer S, Alexandre M, Prague M, Beavogui A, Doumbia S, Kieh M, et al.
Emerg Microbes Infect
. 2024 Nov;
14(1).
PMID: 39559990
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data...
3.
Hejblum B, Ba K, Thiebaut R, Agniel D
Genome Biol
. 2024 Oct;
25(1):281.
PMID: 39478633
A recent study reported exaggerated false positives by popular differential expression methods when analyzing large population samples. We reproduce the differential expression analysis simulation results and identify a caveat in...
4.
Chalouni M, Loubet P, Lhomme E, Ninove L, Barrou B, Blay J, et al.
BMC Infect Dis
. 2024 Sep;
24(1):1049.
PMID: 39333909
Background: We assessed the prognostic value of serological humoral markers measured one month after the last dose of the primary COVID-19 vaccine course for predicting the risk of severe acute...
5.
Wiedemann A, Lhomme E, Huchon M, Foucat E, Bererd-Camara M, Guillaumat L, et al.
Nat Commun
. 2024 Sep;
15(1):7666.
PMID: 39227399
Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck's Ervebo (rVSV-ZEBOV) and Johnson & Johnson's two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year...
6.
White E, Papagno L, Samri A, Sugata K, Hejblum B, Henry A, et al.
Nat Immunol
. 2024 Aug;
25(9):1555-1564.
PMID: 39179934
Human immunodeficiency virus 1 (HIV-1) infection is characterized by a dynamic and persistent state of viral replication that overwhelms the host immune system in the absence of antiretroviral therapy (ART)....
7.
Lacabaratz C, Durand M, Wiedemann A, Foucat E, Surenaud M, Krief C, et al.
J Infect Dis
. 2024 Jul;
231(1):230-240.
PMID: 39012798
Background: The EBL2001 phase 2 trial tested the 2-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine in Europe. Safety and humoral immunogenicity assessments led to European Union market authorization in 2020. Complementary analyses...
8.
Alexandre M, Prague M, Lhomme E, Lelievre J, Wittkop L, Richert L, et al.
Clin Infect Dis
. 2024 May;
79(6):1447-1457.
PMID: 38819800
Background: Analytical treatment interruption (ATI) is the gold standard in HIV research for assessing the capability of new therapeutic strategies to control viremia without antiretroviral treatment (ART). The viral setpoint...
9.
Barry H, Lhomme E, Surenaud M, Nouctara M, Robinson C, Bockstal V, et al.
PLoS Negl Trop Dis
. 2024 Apr;
18(4):e0011500.
PMID: 38603720
Background: The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the...
10.
Pastor Y, Reynard O, Iampietro M, Surenaud M, Picard F, El Jahrani N, et al.
Cell Rep Med
. 2024 Mar;
5(3):101467.
PMID: 38471503
Nipah virus (NiV) has been recently ranked by the World Health Organization as being among the top eight emerging pathogens likely to cause major epidemics, whereas no therapeutics or vaccines...